drugset / Trial / NCT03062501

Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis

NCT03062501

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for painful vaso-occlusive crises .

Timeline

Start
2016-11
Primary completion
2017-04
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified 30 mg/kg
Subject Hydroxyurea Other / unclassified 40 mg/kg

Indications